Lurbinectedin is a chemotherapy drug that is used to treat certain types of cancer, including small cell lung cancer and certain types of sarcoma [2]. The drug works by blocking the activity of an enzyme that is necessary for cancer cells to divide and grow [2]. However, the safety of long-term use of lurbinectedin is not well established.

According to DrugPatentWatch, there are currently no patents listed for lurbinectedin, which suggests that the drug is likely off-patent and available in generic form [1]. This means that there may be multiple manufacturers producing the drug, which could affect its quality and consistency.

MedlinePlus, a website run by the National Institutes of Health, notes that lurbinectedin can cause a number of side effects, including nausea, vomiting, diarrhea, fatigue, and hair loss [2]. The website also warns that the drug can cause serious side effects, such as low blood cell counts and liver damage [2]. It is important for patients taking lurbinectedin to be closely monitored by their healthcare provider for these and other potential side effects.

A recent study published in the journal Cancers found that lurbinectedin was generally well-tolerated in patients with advanced solid tumors, with the most common side effects being nausea, fatigue, and decreased appetite [3]. However, the study did not evaluate the long-term safety of the drug.

Overall, while lurbinectedin may be effective in treating certain types of cancer, its long-term safety is not well established. Patients taking the drug should be closely monitored for potential side effects and should discuss any concerns with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://medlineplus.gov/druginfo/meds/a620049.html
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271468/